JPMorgan Funds - Global Healthcare Fund D (acc) - USDRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 18.5 | 11.0 | 1.1 | -4.0 | 3.9 | |
+/-Cat | 1.1 | 1.6 | 5.8 | -0.9 | 0.2 | |
+/-B’mrk | - | -7.2 | -4.7 | -1.5 | -3.5 | |
Category: Sector Equity Healthcare | ||||||
Category Benchmark: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 21/11/2024 | USD 411.74 | |
Day Change | 0.44% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0432979960 | |
Fund Size (Mil) 21/11/2024 | USD 3977.30 | |
Share Class Size (Mil) 21/11/2024 | USD 214.81 | |
Max Initial Charge | - | |
Ongoing Charge 18/07/2024 | 2.70% |
Investment Objective: JPMorgan Funds - Global Healthcare Fund D (acc) - USD |
To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Dominic Valder 05/10/2022 | ||
Bartjan van Hulten 28/02/2024 | ||
Inception Date 02/10/2009 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for JPMorgan Funds - Global Healthcare Fund D (acc) - USD | 31/10/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 8.86 |
UnitedHealth Group Inc | Healthcare | 8.04 |
AbbVie Inc | Healthcare | 6.26 |
Novo Nordisk AS Class B | Healthcare | 5.78 |
Thermo Fisher Scientific Inc | Healthcare | 4.41 |
Increase Decrease New since last portfolio | ||
JPMorgan Funds - Global Healthcare Fund D (acc) - USD |